| scholarly article | Q13442814 |
| P50 | author | Shabnum Patel | Q87592399 |
| Joseph J Eron | Q87874621 | ||
| Catherine M Bollard | Q91774704 | ||
| Nancie M Archin | Q106613342 | ||
| JoAnn D Kuruc | Q106614334 | ||
| David M. Margolis | Q37380199 | ||
| P2093 | author name string | Nilu Goonetilleke | |
| Cynthia L Gay | |||
| Patrick J Hanley | |||
| C Russell Cruz | |||
| Julia A Sung | |||
| Matthew L Clohosey | |||
| Tamara Tripic | |||
| Clio M Rooney | |||
| Lauren Roesch | |||
| P2860 | cites work | Common genetic variation and the control of HIV-1 in humans | Q21092450 |
| Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid | Q24596282 | ||
| Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production | Q24676570 | ||
| T-cell therapies for HIV | Q26866079 | ||
| Emerging strategies to deplete the HIV reservoir | Q27023877 | ||
| Human leukocyte antigens and HIV type 1 viral load in early and chronic infection: predominance of evolving relationships | Q28394085 | ||
| Resistance mutations and CTL epitopes in archived HIV-1 DNA of patients on antiviral treatment: toward a new concept of vaccine | Q28534573 | ||
| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation | Q29417018 | ||
| Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy | Q29615993 | ||
| Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 | ||
| Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood | Q33633262 | ||
| Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience | Q34039992 | ||
| HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat | Q34106191 | ||
| Additive contribution of HLA class I alleles in the immune control of HIV-1 infection | Q34120809 | ||
| Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. | Q34273968 | ||
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 | ||
| Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection | Q34315612 | ||
| HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo | Q35029956 | ||
| B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers | Q35058635 | ||
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins | Q35068768 | ||
| Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses | Q35130519 | ||
| Selective HDAC inhibition for the disruption of latent HIV-1 infection | Q35227888 | ||
| Eradicating HIV-1 infection: seeking to clear a persistent pathogen | Q35252186 | ||
| Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations | Q35521811 | ||
| Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys. | Q45326279 | ||
| Depletion of CD8+ cells in sooty mangabey monkeys naturally infected with simian immunodeficiency virus reveals limited role for immune control of virus replication in a natural host species | Q45403270 | ||
| Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. | Q45760355 | ||
| Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals | Q45862722 | ||
| Adoptive Immunotherapy of Viral Infections: Should Infectious Disease Embrace Cellular Immunotherapy? | Q47613802 | ||
| In vivo migration and function of transferred HIV-1-specific cytotoxic T cells | Q47995100 | ||
| Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. | Q49086716 | ||
| Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. | Q52007779 | ||
| In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. | Q52050894 | ||
| Design and analysis of serial limiting dilution assays with small sample sizes. | Q52224088 | ||
| Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication. | Q52608538 | ||
| Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal | Q57425155 | ||
| Re-emergence of HIV after stopping therapy | Q59060012 | ||
| Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression | Q71803154 | ||
| Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy | Q35653249 | ||
| CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo | Q35776868 | ||
| Definition of the viral targets of protective HIV-1-specific T cell responses | Q35800157 | ||
| Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir | Q35812943 | ||
| Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat | Q36086345 | ||
| Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies | Q36148964 | ||
| Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells | Q36266486 | ||
| IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa | Q36286857 | ||
| Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus | Q36305254 | ||
| Migratory properties of naive, effector, and memory CD8(+) T cells | Q36369485 | ||
| Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 | ||
| Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy | Q36499290 | ||
| Acute HIV-1 infection in the Southeastern United States: a cohort study | Q36509575 | ||
| HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race? | Q36759787 | ||
| HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression | Q36781531 | ||
| New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma | Q36891848 | ||
| Dilution assay statistics | Q37073320 | ||
| HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703 | Q37081581 | ||
| The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection | Q37273195 | ||
| Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes | Q37334642 | ||
| Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells | Q37393518 | ||
| T-cell therapy in the treatment of post-transplant lymphoproliferative disease | Q38026758 | ||
| HIV and HLA class I: an evolving relationship | Q38045636 | ||
| Cytotoxic T lymphocytes for leukemia and lymphoma | Q38361829 | ||
| Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir | Q38777005 | ||
| Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c | Q39028785 | ||
| IL-15 induces the expression of chemokines and their receptors in T lymphocytes. | Q39349797 | ||
| HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal | Q40080802 | ||
| Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells | Q40084640 | ||
| Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency | Q40120304 | ||
| CXCR5-Dependent Entry of CD8 T Cells into Rhesus Macaque B-Cell Follicles Achieved through T-Cell Engineering | Q40290381 | ||
| CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy. | Q40532397 | ||
| Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells | Q41928841 | ||
| In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation | Q43572619 | ||
| Improving T-cell therapy for epstein-barr virus lymphoproliferative disorders | Q43714922 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular biology | Q7202 |
| pharmacology | Q128406 | ||
| drug discovery | Q1418791 | ||
| molecular medicine | Q3523816 | ||
| P304 | page(s) | 2496-2506 | |
| P577 | publication date | 2018-09-21 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals | |
| P478 | volume | 26 |
| Q90630528 | Chronic inflammation mediates brain injury in HIV infection: relevance for cure strategies |
| Q90707628 | Curing HIV: Seeking to Target and Clear Persistent Infection |
| Q64100454 | Harnessing CD8 T Cells Under HIV Antiretroviral Therapy |
| Q92134571 | Measuring the Success of HIV-1 Cure Strategies |
| Q95272150 | Nanoparticle-Based Immunoengineered Approaches for Combating HIV |
| Q60046873 | Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction |
| Q98291353 | Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation |
Search more.